β-Caryophyllene: The Dietary Cannabinoid

β-Caryophyllene (BCP) represents a groundbreaking anomaly in phytocannabinoid science. Unlike other terpenes that influence the olfactory system or alter blood-brain barrier permeability, BCP is recognized as a functional dietary cannabinoid. It is famously found in black pepper, cloves, and rosemary.

A key 2008 study published in the Proceedings of the National Academy of Sciences (PNAS) definitively established that β-caryophyllene selectively binds to the CB2 cannabinoid receptor (Gertsch et al., 2008). Because CB2 receptors are primarily located in the peripheral organs and the immune system (rather than the central nervous system), BCP provides potent anti-inflammatory and immunomodulatory effects without the psychoactive toxicity associated with CB1 agonism.

In addition to inflammation management, subsequent studies (Bahi et al., 2014) have demonstrated that BCP exerts anxiolytic (anti-anxiety) and antidepressant effects, making Caryophyllene-dominant cultivars ideal for patients seeking systemic relief while maintaining cognitive clarity.

In fact, the therapeutic implications of CB2 receptor agonism extend into neuroprotection and gastrointestinal health. Clinical models have demonstrated that beta-caryophyllene can mitigate inflammatory bowel disease (IBD) symptoms and attenuate neuroinflammation associated with degenerative diseases. This makes caryophyllene a critical target for breeders focused on systemic, non-intoxicating medical applications.